#demyelinating

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves.

Key Highlight of Chronic Inflammatory Demyelinating Polyneuropathy Market

In 2017, prevalent cases of typical and atypical CIDP in the US varied as 10,342 and 9,936, respectively.

According to DelveInsight estimates, the total prevalent population of CIDP in 7MM was found to be 44,843 in 2017. 

Among the 7MM countries, the United States has a higher population of CIDP.

According to DelveInsight’s analysis, Males are at more at risk to develop CIDP than Females

For more detais on  Chronic Inflammatory Demyelinating Polyneuropathy 

Market visit:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2017 Just Published

  Summary latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline landscape. Request For Full Report…

Cell therapy successfully promotes axon remyelination in an animal model. Thoughts health innovators?

Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons. This demyelination can be caused by an autoimmune response or impaired myelin production by oligodendrocytes. Now, a study from Duke University shows that a cell therapy product called DUOC-01 can accelerate remyelination of axons…